avelumab

01/01/2018 - "In conclusion, currently available data suggest that avelumab presents a clinically beneficial new treatment option for metastatic MCC, a rare but aggressive cancer associated with a poor prognosis."
01/01/2020 - "Consequently, the efficacy of avelumab in mouse tumor models is dependent on Cxcr3 and Cxcl9, and baseline levels of Cxcl9 in patients treated with avelumab are associated with clinical response and overall survival. "
09/06/2023 - "The trial showed that avelumab maintenance treatment helped people with advanced urothelial cancer live longer than people who were not treated with avelumab. "
09/06/2023 - "Avelumab also helped people have a longer time without their cancer getting worse. "
10/01/2022 - "Though the PD-L1 checkpoint inhibitor avelumab has shown efficacy in the treatment of some types of cancer, improved treatment strategies are desperately needed. "

06/13/2023 - "Avelumab in metastatic collecting duct carcinoma of the kidney: a case report."
01/01/2022 - "Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma."
10/24/2019 - "Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial."
01/01/2019 - "In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. "
11/01/2022 - "An 84 year-old female with a right renal cell carcinoma invading the vena cava received two cycles of avelumab plus axitinib. "

01/01/2020 - "Baseline interviews described the patients' challenging journeys before being correctly diagnosed with Merkel cell carcinoma, the negative psychological burden of living with a symptomless disease and the hope for avelumab to be a successful therapy. "
04/01/2019 - "Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma."
01/01/2019 - "Unknown primary Merkel cell carcinoma responding well to first-line treatment with avelumab."
01/01/2018 - "Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial."
01/01/2022 - "Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study."

08/02/2023 - "Conclusion: Avelumab first-line maintenance is likely to be a cost-effective treatment for locally advanced or metastatic urothelial carcinoma in Scotland. "
10/04/2023 - "Data from JAVELIN-100 was utilized which is a phase III study of avelumab in first-line maintenance treatment in patients with urothelial carcinoma; this clinical study demonstrated superiority of avelumab versus best-supportive care leading to approval in the United States, Europe, and other countries. "
09/06/2023 - "The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma."
08/02/2023 - "This study looked at the costs of avelumab when given as maintenance treatment for people in Scotland with advanced urothelial carcinoma, compared with the longer survival and other benefits that it provides. "
01/01/2023 - "Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up."

01/01/2019 - "Patients received avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study. "
01/01/2019 - "Participants received avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study. "
01/01/2023 - "Avelumab was delivered every other week, and SBRT was delivered to one lesion in three to five fractions (minimum of 30 Gy) followed by continuation of avelumab up to 24 months or until disease progression. "
11/24/2022 - "However, disease progression as best response was noticed for 37% of patients under Avelumab as maintenance treatment. "
01/01/2021 - "Patient cases 1 and 2 received avelumab alone and experienced rapid disease progression according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). "